Epogen
(Epoetin Alfa)Phase 3Small molecule
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.This drug is used to treat anemia (low red blood cell counts) caused by kidney disease, chemotherapy, or certain medical treatments. It works by stimulating your body to produce more red blood cells, which helps prevent fatigue and the need for blood transfusions.[1] Epogen is currently being investigated across 9 indications[3], with its most advanced program in Phase 3.[1]
Epogen is one of 316 small molecule programs targeting Chronic Kidney Disease. It is currently in Phase 3.
9
Indications
169
Total Trials
8
Active Trials
315
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
172 competitors in Chronic Kidney Disease
#DrugCompanyPhaseTrials
1Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Uloric
TakedaPreclinical
Sovaldi
GileadPreclinical
Glucotrol
PfizerPreclinical
Vemlidy
GileadPreclinical
Lorelco
SanofiPreclinical
Activase
RochePreclinical
Flomax
SanofiPreclinical
Verquvo
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
PROCRIT
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Anemia52 trials
A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia
Terminated·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00210795·12 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00210795·12 enrolledShow 49 more trials
A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00341055·69 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00341055·69 enrolledResearch Into the Treatment of Anemia for Critically Ill Patients Admitted to Intensive Care Units (ICU)
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00091910·1,460 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00091910·1,460 enrolledA Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia
Terminated·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00228995·9 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00228995·9 enrolledEpoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum Chemotherapy
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00270127·375 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00270127·375 enrolledA Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia as a Result of Cancer Treatment With Cisplatin, a Platinum-containing Chemotherapy Drug
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00269997·72 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00269997·72 enrolledAlternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00210743·67 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00210743·67 enrolledAlternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00338299·51 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00338299·51 enrolledTreatment of Anemia in Diabetic Subjects With CKD
Terminated·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00240734·11 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00240734·11 enrolledTreatment Program for Anemia in AIDS Patients
Completed·—·N/A·NCT00002022
The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00270166·201 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00270166·201 enrolledA Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in AIDS Patients With Anemia Caused Both by Their Disease and by AZT (Zidovudine, an Antiviral Drug) Given as Treatment for Their Disease
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00269945·60 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00269945·60 enrolledTreatment of Chronic Anemia With Epoetin Alfa in Elderly
Unknown status·RResearch and Education Foundation of Michael Reese Hospital·Phase 2·NCT00337441·62 enrolled
Chronic Kidney Disease17 trials
Show 14 more trials
A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease.
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00212875·267 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00212875·267 enrolled
Effectiveness7 trials
Show 4 more trials
A Study to Evaluate the Safety of Epoetin Alfa and Its Effectiveness in Facilitating the Presurgical Collection of Blood From Anemic Patients for Possible Self-transfusion During and After Scheduled Joint Surgery.
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00270062·77 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00270062·77 enrolledA Study to Determine the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Not Anemic and Who Will be Undergoing Orthopedic or Heart and Blood Vessel Surgery
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2/3·NCT00270075·80 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2/3·NCT00270075·80 enrolledA Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Facilitating the Presurgical Collection of Blood to be Used for Self-donation During Surgery on the Spine, Hip, or Knee.
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00270140·17 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00270140·17 enrolledMyelodysplastic Syndromes7 trials
A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion
Terminated·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00695396·25 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00695396·25 enrolled
Show 4 more trials
Efficacy and Safety5 trials
Show 2 more trials
Study of the Efficacy and Safety of Epoetin Alfa Administered Weekly in Patients With Gastric or Rectal Cancers Undergoing a Treatment Plan of Preoperative Chemotherapy and Radiation Therapy, Followed by Surgery
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00036400·60 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00036400·60 enrolled48 more indications
Breast Cancer4 trials
Intravenous Administration4 trials
Blood Transfusion4 trials
Myelodysplastic Syndrome4 trials
Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome
Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00003681·50 enrolled
Chemotherapy3 trials
Quality of Life3 trials
Immunodeficiency3 trials
A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo for the Treatment of Anemia in AIDS (Acquired Immunodeficiency Syndrome) Patients With Anemia Caused by the Disease and by Zidovudine (AZT) Therapy
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00270270·63 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00270270·63 enrolledA Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in AIDS (Acquired Immunodeficiency Syndrome) Patients With Anemia Caused Both by Their Disease and by AZT (Zidovudine, an Antiviral Drug) Given as Treatment for Their Disease
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00270010·72 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00270010·72 enrolledA Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo for the Treatment of Anemia in Patients With Acquired Immunodeficiency Syndrome (AIDS) Who Are Receiving Zidovudine (AZT) Therapy
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00270283·102 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00270283·102 enrolledFatigue3 trials
End-Stage Renal Disease2 trials
Chronic Lymphocytic Leukemia2 trials
Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00270049·195 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00270049·195 enrolledRenal insufficiency2 trials
Head and Neck Cancer2 trials
Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Head and Neck Cancer
Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00017277·47 enrolled
Erythropoietin2 trials
Orthopedic Surgery2 trials
A Study of the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Undergoing Orthopedic Surgery and Who Have Low Hematocrit Levels (the Percent of Red Blood Cells in Whole Blood)
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2/3·NCT00270114·55 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2/3·NCT00270114·55 enrolledPROCRIT and Short-Term Outcomes in Orthopedic Surgery
Terminated·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00236405·6 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00236405·6 enrolledSafety and Efficacy2 trials
A Study to Confirm the Safety and Efficacy of Epoetin Alfa (PROCRIT) Administered Perioperatively vs. the Standard of Care in Blood Conservation in Patients Undergoing Major Elective Spinal Surgery (SPINE Study)
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00211146·680 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00211146·680 enrolledHemoglobin2 trials
Multiple Myeloma2 trials
Prostate Cancer2 trials
Radiation Therapy1 trial
Myocardial Infarction1 trial
Neutropenia1 trial
Critically Ill Patients1 trial
Pharmacokinetic/ Pharmacodynamic Study of Epoetin Alfa (PROCRIT) in Critically Ill Patients.
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00210756·60 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2·NCT00210756·60 enrolledSubarachnoid Hemorrhage1 trial
Hemodialysis1 trial
Rheumatoid Arthritis1 trial
Delayed Graft Function1 trial
Hip Replacement Surgery1 trial
Blood Loss During Surgery1 trial
A Study to Determine the Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Non-anemic Patients Who Are Undergoing Orthopedic, Heart and Blood Vessel, or Breast Reduction Surgery; Performed in Combination With a Procedure to Reduce Blood Loss During Surgery.
Completed·Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2/3·NCT00270023·112 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 2/3·NCT00270023·112 enrolledAcute Myocardial Infarction1 trial
Kidney Transplant1 trial
Study of Epoetin Alfa to Treat Anemia After Kidney Transplantation
Terminated·—·N/A·NCT01290328·100 enrolled
Liver Transplant1 trial
EVR and EPO for Liver Transplant Tolerance
Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT06832189·20 enrolled
Red Blood Cell Transfusions1 trial
Granulocyte Colony Stimulating Factor1 trial
Pancreatic Cancer1 trial
Cervical Cancer1 trial
Brain Injury1 trial
Erythropoietin in Traumatic Brain Injury (EPO-TBI)
Completed·—·Phase 3·NCT00987454·606 enrolled
Thalassemia1 trial
Phase II Study of Arginine Butyrate With or Without Epoetin Alfa in Patients With Thalassemia Intermedia
Completed·—·Phase 2·NCT00006136·15 enrolled
Kidney Disease1 trial
Acute Myeloid Leukemia1 trial
Unspecified3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Epoetin Alfa. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details